Fever Control Using External Cooling in Septic Shock A Randomized Controlled Trial

被引:185
|
作者
Schortgen, Frederique [2 ]
Clabault, Karine [3 ]
Katsahian, Sandrine [1 ]
Deyaquet, Jerome [4 ]
Mercat, Alain [5 ]
Deye, Nicolas [6 ]
Dellamonica, Jean [7 ]
Bouadma, Lila [8 ]
Cook, Fabrice
Beji, Olfa
Brun-Buisson, Christian
Lemaire, Francois
Brochard, Laurent [2 ,9 ]
机构
[1] Grp Hosp Henri Mondor, APHP, Unite Rech Clin, Creteil, France
[2] Inst Natl Sante & Rech Med, Fac Med, U955, Creteil, France
[3] Univ Rouen Ctr Hosp, Rouen, France
[4] Hop Foch, Suresnes, France
[5] Ctr Hosp Univ Angers, Angers, France
[6] Hop Lariboisiere, AP HP, F-75475 Paris, France
[7] Univ Nice, Ctr Hosp, Nice, France
[8] Hop Bichat Claude Bernard, AP HP, F-75877 Paris 18, France
[9] Univ Geneva, Hop Univ Geneva, Geneva, Switzerland
关键词
septic shock; fever; intensive care unit; vasopressor agents; INTENSIVE-CARE-UNIT; SEVERE SEPSIS; HYPOTHERMIA; NOREPINEPHRINE; HEMOFILTRATION; ANTIPYRETICS; MANAGEMENT; OXYGEN; ACETAMINOPHEN; HEMODYNAMICS;
D O I
10.1164/rccm.201110-1820OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: Fever control may improve vascular tone and decrease oxygen consumption, but fever may contribute to combat infection. Objectives: To determine whether fever control by external cooling diminishes vasopressor requirements in septic shock. Methods: In a multicenter randomized controlled trial, febrile patients with septic shock requiring vasopressors, mechanical ventilation, and sedation were allocated to external cooling (n = 101) to achieve normothermia (36.5-37 degrees C) for 48 hours or no external cooling (n = 99). Vasopressors were tapered to maintain the same blood pressure target in the two groups. The primary endpoint was the number of patients with a 50% decrease in baseline vasopressor dose after 48 hours. Measurements and Main Results: Body temperature was significantly lower in the cooling group after 2 hours of treatment (36.8 +/- 0.7 vs. 38.4 +/- 1.1 degrees C; P < 0.01). A 50% vasopressor dose decrease was significantly more common with external cooling from 12 hours of treatment (54 vs. 20%; absolute difference, 34%; 95% confidence interval [95% Cl], -46 to -21; P < 0.001) but not at 48 hours (72 vs. 61%; absolute difference, 11%; 95% Cl, -23 to 2). Shock reversal during the intensive care unit stay was significantly more common with cooling (86 vs. 73%; absolute difference, 13%; 95% Cl, 2 to 25; P = 0.021). Day-14 mortality was significantly lower in the cooling group (19 vs. 34%; absolute difference, -16%; 95% Cl, -28 to -4; P = 0.013). Conclusions: In this study, fever control using external cooling was safe and decreased vasopressor requirements and early mortality in septic shock.
引用
收藏
页码:1088 / 1095
页数:8
相关论文
共 50 条
  • [31] EFFECTS OF SHENFU INJECTION ON SUBLINGUAL MICROCIRCULATION IN SEPTIC SHOCK PATIENTS: A RANDOMIZED CONTROLLED TRIAL
    Wang, Shiwei
    Liu, Guoxiang
    Chen, Li
    Xu, Xinhui
    Jia, Tianyuan
    Zhu, Changqing
    Xiong, Jianfei
    SHOCK, 2022, 58 (03): : 196 - 203
  • [32] Role of dexmedetomidine in modifying immune paralysis in patients with septic shock: randomized controlled trial
    Mohamed Elayashy
    Eman A. Elsayed
    Ahmed M. Mukhtar
    Sahar Kasem
    Sara A. Elmetwally
    Sara Habib
    Walaa Abdelfattah
    Doaa Ghaith
    Amr Hussein
    Intensive Care Medicine Experimental, 11
  • [33] Lung ultrasound–guided fluid resuscitation in neonatal septic shock: A randomized controlled trial
    Dabin Huang
    Chuming You
    Xiaowei Mai
    Lin Li
    Qiong Meng
    Zhenyu Liang
    European Journal of Pediatrics, 2024, 183 : 1255 - 1263
  • [34] Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial
    McIntyre, Lauralyn A.
    Fergusson, Dean
    Cook, Deborah J.
    Rankin, Nigel
    Dhingra, Vinay
    Granton, John
    Magder, Sheldon
    Stiell, Ian
    Taljaard, Monica
    Hebert, Paul C.
    CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 2008, 55 (12): : 819 - 826
  • [35] Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial
    Arabi, Yaseen M.
    Aljumah, Abdulrahman
    Dabbagh, Ousama
    Tamim, Hani M.
    Rishu, Asgar H.
    Al-Abdulkareem, Abdulmajeed
    Al Knawy, Bandar
    Hajeer, Ali H.
    Tamimi, Waleed
    Cherfan, Antoine
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (18) : 1971 - 1977
  • [36] Triiodothyronine Administration in a Model of Septic Shock: A Randomized Blinded Placebo-Controlled Trial
    Maiden, Matthew J.
    Chapman, Marianne J.
    Torpy, David J.
    Kuchel, Timothy R.
    Clarke, Iain J.
    Nash, Coralie H.
    Fraser, Jonathan D.
    Ludbrook, Guy L.
    CRITICAL CARE MEDICINE, 2016, 44 (06) : 1153 - 1160
  • [37] Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial
    Francois, Bruno
    Wittebole, Xavier
    Ferrer, Ricard
    Mira, Jean-Paul
    Dugernier, Thierry
    Gibot, Sebastien
    Derive, Marc
    Olivier, Aurelie
    Cuvier, Valerie
    Witte, Stephan
    Pickkers, Peter
    Vandenhende, Francois
    Garaud, Jean-Jacques
    Sanchez, Miguel
    Salcedo-Magguilli, Margarita
    Laterre, Pierre-Francois
    INTENSIVE CARE MEDICINE, 2020, 46 (07) : 1425 - 1437
  • [38] Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial
    Bruno François
    Xavier Wittebole
    Ricard Ferrer
    Jean-Paul Mira
    Thierry Dugernier
    Sébastien Gibot
    Marc Derive
    Aurélie Olivier
    Valérie Cuvier
    Stephan Witte
    Peter Pickkers
    François Vandenhende
    Jean-Jacques Garaud
    Miguel Sánchez
    Margarita Salcedo-Magguilli
    Pierre-François Laterre
    Intensive Care Medicine, 2020, 46 : 1425 - 1437
  • [39] Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial
    Meng, Jian-biao
    Hu, Ma-hong
    Lai, Zhi-zhen
    Ji, Chun-lian
    Xu, Xiu-juan
    Zhang, Geng
    Tian, Shuyuan
    MEDICAL SCIENCE MONITOR, 2016, 22 : 1486 - 1496
  • [40] TREATMENT OF SEPTIC SHOCK WITH A PROTEASE INHIBITOR IN A CANINE MODEL - A PROSPECTIVE, RANDOMIZED, CONTROLLED TRIAL
    TANI, T
    AOKI, H
    YOSHIOKA, T
    LIN, KJ
    KODAMA, M
    CRITICAL CARE MEDICINE, 1993, 21 (06) : 925 - 930